Immune cell therapy shows promise for Tough-to-Treat lymphoma
Disease control
Completed
This trial tested a new therapy called AB-101, made from natural killer (NK) cells, in 45 people with B-cell non-Hodgkin lymphoma that had come back or stopped responding to treatment. The study looked at AB-101 alone or combined with other drugs like rituximab or chemotherapy. T…
Phase: PHASE1, PHASE2 • Sponsor: Artiva Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC